Everolimus vs. rapamycin for treating diabetic nephropathy in diabetic mouse model

Abstract

In order to evaluate the effectiveness of everolimus vs. rapamycin in the treatment of diabetic nephropathy, 8-week old diabetic (db/db) mice received everolimus (2 mg/kg every day) or rapamycin (2 mg/kg every day) for 4 weeks or 12 weeks respectively. Blood and 24-h urine samples were collected for biochemical tests. One kidney from each mouse was homogenized for protein analysis and the other was removed for histological analysis. The expression levels of transforming growth factor-β1 (TGF-β1)and phospho-p70s6k were detected by using ELISA and Western blot, respectively in the renal tissue as well as in mesengial cell culture samples. Everolimus was significantly more effective than rapamycin in improving indexes of renal function and glomerular hypertrophy, and in decreasing accumulation and expansion of the extracellular matrix. However, everolimus inhibited TGF-β1 secretion and p70s6k phosphorylation induced by high glucose in vitro less efficiently than rapamycin at the same dose. Everolimus was more effective than rapamycin in preventing diabetic nephropathy in vivo, which may be contributed to the fact that everolimus has better bioavailability and a higher oral absorption rate.

Keywords

db/db mice / diabetic nephropathy / everolimus / mammalian target of rapamycin / mesangial cells

References

[1] RemuzziG., SchieppatiA., RuggenentiP.. Clinical practice. Nephropathy in patients with type 2 diabetes. New Eng J Med, 2002, 346(15): 1145-1151

[2] CooperM.E.. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet, 1998, 352(9123): 213-219

[3] AwadA.S., HuangL., YeH., et al.. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol, 2006, 290(4): F828-837

[4] GrossJ.L., de AzevedoM.J., SilveiroS.P., et al.. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 2005, 28(1): 164-176

[5] KDOQI Clinical Practice GuidelinesClinical Practice Recommendations for DiabetesChronic Kidney Disease.. . Am J Kidney Dis, 2007, 49(Suppl2): S12-S154

[6] MolitchM.E., DeFronzoR.A., FranzM.J., et al.. Nephropathy in diabetes. Diabetes Care, 2004, 27(Suppl1): S79-S83

[7] LloberasN., CruzadoJ.M., FranquesaM., et al.. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol, 2006, 17(5): 1395-1404

[8] SakaguchiM., IsonoM., IsshikiK., et al.. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun, 2006, 340(1): 296-301

[9] SataranatarajanK., MariappanM.M., LeeM.J., et al.. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol, 2007, 171(6): 1733-1742

[10] MoriH., InokiK., MasutaniK., et al.. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun, 2009, 10384(4): 471-475

[11] LeeC.H., InokiK., GuanK.L.. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol, 2007, 47: 443-467

[12] ChenJ.K., ChenJ., NeilsonE.G., et al.. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol, 2005, 16(5): 1384-1391

[13] FraenkelM., Ketzinel-GiladM., AriavY., et al.. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes, 2008, 57(4): 945-957

[14] ChungJ., KuoC.J., CrabtreeG.R., et al.. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell, 1992, 69(7): 1227-1236

[15] CohenM.P., SharmaK., GuoJ., et al.. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. Exp Nephrol, 1998, 6(3): 226-233

[16] FingarD.C., BlenisJ.. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004, 23(18): 3151-3171

[17] YangY., WangJ., QinL., et al.. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol, 2007, 27(5): 495-502

[18] WolfG.. Molecular mechanisms of diabetic renal hypertrophy: role of p27Kip1. Kidney Int, 1999, 56(4): 1262-1265

[19] ShanklandS.J., ScholeyJ.W., LyH., et al.. Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int, 1994, 46(2): 430-442

[20] ZiyadehF.N., SharmaK., EricksenM., et al.. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest, 1994, 93(2): 536-542

[21] BenigniA., ZojaC., CornaD., et al.. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol, 2003, 14(7): 1816-1824

[22] SchulerW., SedraniR., CottensS., et al.. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 1997, 64(1): 36-42

[23] CroweA., BruelisauerA., DuerrL., et al.. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos, 1999, 27(5): 627-632

[24] KovarikJ.M., HartmannS., FigueiredoJ., et al.. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother, 2002, 36(6): 981-985

[25] KirchnerG.I., Meier-WiedenbachI., MannsM.P.. Clinical pharmacokinetics of everolimus. Clin pharmacokinet, 2004, 43(2): 83-95